In severe hepatic impairment, which dosing description applies to Lurasidone?

In severe hepatic impairment, which dosing description applies to Lurasidone?

• A. Start at 50 mg/day, increased by 25-50 mg/day
• B. Start at 10 mg/day, increased by 10-25 mg/day
• C. Start at 15 mg/day, increased by 5-10 mg/day
• D. Start at 25 mg/day, increased by 25-50 mg/day

Answer: (D)

In severe hepatic impairment, the body can’t clear lurasidone as efficiently, so exposure to the drug rises. Lurasidone is mainly metabolized by the liver (CYP3A4), and when liver function is greatly reduced, clearance drops and plasma levels can become too high if the dose is too large or increased too quickly. The dosing approach here uses a low starting point and cautious titration to balance effectiveness with safety. Starting at 25 mg per day and increasing by 25–50 mg per day provides a gentler ramp to achieve therapeutic levels, while giving room to monitor tolerability and avoid excessive exposure that could lead to adverse effects. Higher starting doses or rapid, larger increments would push plasma levels higher than is safe in severe liver impairment. This approach aligns with the principle of lowering exposure in severe hepatic dysfunction and adjusting gradually based on response and safety.

In severe hepatic impairment, the body can’t clear lurasidone as efficiently, so exposure to the drug rises. Lurasidone is mainly metabolized by the liver (CYP3A4), and when liver function is greatly reduced, clearance drops and plasma levels can become too high if the dose is too large or increased too quickly. The dosing approach here uses a low starting point and cautious titration to balance effectiveness with safety.

Starting at 25 mg per day and increasing by 25–50 mg per day provides a gentler ramp to achieve therapeutic levels, while giving room to monitor tolerability and avoid excessive exposure that could lead to adverse effects. Higher starting doses or rapid, larger increments would push plasma levels higher than is safe in severe liver impairment. This approach aligns with the principle of lowering exposure in severe hepatic dysfunction and adjusting gradually based on response and safety.